Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mette Borg Clausen

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Ugeskrift for Laeger|June 11, 2015
[Chemotherapy in the second and third trimester of pregnancy is compatible with the delivery of a healthy infant]Berit Woetmann Pedersen, Mette Borg Clausen, Jette Sønderskov Gørløv, et al.
Ugeskrift for Laeger|August 5, 2015
[Cancer in pregnancy]Berit Woetmann Pedersen, Lone Storgaard, Mette Borg Clausen, et al.
Acta Oncologica (Stockholm, Sweden)|September 1, 2023
Labor market affiliation of patients with myeloproliferative neoplasms: a population-based matched cohort studyLise Skovgaard Svingel, Sarah Friis Christensen, Anders Kjærsgaard, et al.
European Journal of Haematology|July 28, 2022
Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort studySarah Friis Christensen, Lise Skovgaard Svingel, Anders Kjaersgaard, et al.
Frontiers in Oncology|March 15, 2021
Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With <i>CALR</i>-Mutant Chronic Myeloproliferative NeoplasmsJacob Handlos Grauslund, Morten Orebo Holmström, Nicolai Grønne Jørgensen, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Ugeskrift for Laeger|June 11, 2015
[Chemotherapy in the second and third trimester of pregnancy is compatible with the delivery of a healthy infant]Berit Woetmann Pedersen, Mette Borg Clausen, Jette Sønderskov Gørløv, et al.
Ugeskrift for Laeger|August 5, 2015
[Cancer in pregnancy]Berit Woetmann Pedersen, Lone Storgaard, Mette Borg Clausen, et al.
Acta Oncologica (Stockholm, Sweden)|September 1, 2023
Labor market affiliation of patients with myeloproliferative neoplasms: a population-based matched cohort studyLise Skovgaard Svingel, Sarah Friis Christensen, Anders Kjærsgaard, et al.
European Journal of Haematology|July 28, 2022
Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort studySarah Friis Christensen, Lise Skovgaard Svingel, Anders Kjaersgaard, et al.
Frontiers in Oncology|March 15, 2021
Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With <i>CALR</i>-Mutant Chronic Myeloproliferative NeoplasmsJacob Handlos Grauslund, Morten Orebo Holmström, Nicolai Grønne Jørgensen, et al.
Pageof 1